TWiV 817: COVID-19 clinical update #84 with Dr. Daniel Griffin
About this episode
In COVID-19 clinical update #84, Dr. Griffin discusses childrens' antibody response to vaccination, phase 3 results of Novavax vaccine, heterologous vaccination, antithrombotic therapy, EUA for molnupiravir, phase 3 results of AZD7442, serum ferritin levels and outcomes, heparin therapy, and WHO strategy for global vaccination.
Become a patron of TWiV!
Links for this episode
- Antibody profiles after mRNA vaccination in children (bioRxiv)
- Novavax vaccine phase 3 results (medRxiv)
- Heterologous vaccine boosters (medRxiv)
- Antithrombotic therapy outcomes (JAMA)
- Molnupiravir EUA submitted (Merck)
- AZD7442 phase 3 results (AstraZeneca)
- Serum ferritin levels and disease outcome (JAMA)
- Heparin efficacy (JAMA)
- WHO strategy to vaccinate world (WHO)
- Letters read on TWiV 817
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology
TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology
TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology
TWiV 1307: My heart breaks for flu
This Week in Virology
TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology